Correlation of incontinence impact questionnaire score in overactive bladder syndrome cases with urodynamic findings

Jai B. Sharma, Mukul Chauhan, Neerja Bhatla, Amlesh Seth, Rajesh Kumari, Bharti Uppal, Janmeeta Singh


Background: Overactive bladder syndrome (OAB) is a common condition. The aim of the present study was to correlate the incontinence impact questionnaire (IIQ) score with urodynamic studies in patients of overactive bladder syndrome.

Methods: It was a prospective study performed in a tertiary referral centre on 60 women with symptomatology of OAB. IIQ score was calculated and urodynamic studies were performed in all patients in which detrusor overactivity, maximum flow rate of urine per second (Qmax) and voiding time in seconds was calculated in all women.

Results: The mean age was 42.3±9.91 years, mean body mass index was 24.7±2.71 kg/m2, mean parity was 2.4 and mean serum creatinine level was 0.84±0.21 mg/dl. Symptoms seen were urgency (100%), frequency (100%), urge incontinence (95.0%) and nocturia (76.6%). IIQ score ranged from 7-20 with mean being 12.27±3.38. OAB was mild in 36.6%, moderate in 41.66% and severe in 21.66% patients. On urodynamic studies, detrusor overactivity was present in 75% cases being 59% in mild, 80% in moderate and 76.92% in severe OAB. Mean Qmax increased with severity of OAB and was 29.55ml/second in mild OAB, 30.36ml/second in moderate OAB and 31.59 ml/second in severe OAB. Mean voiding time decreased with severity of OAB and was 33.44 seconds in mild OAB, 32.14 seconds in moderate OAB and 31.47 seconds in severe OAB.

Conclusions: IIQ score and urodynamic studies are useful in diagnosis and quantification of OAB syndrome.


Incontinence impact questionnaire score, Overactive bladder syndrome, Qmax, Urge incontinence, Urodynamic studies, Voiding time

Full Text:



Bo K, Frawley HC, Haylen BT, Abramov Y, Almeida FG, Berghmans B, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Int Urogynecol J. 2017;28(2):191-213.

Cardozo L, Staskin D, Currie B, Wiklund I, Globe D, Signori M, et al. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J. 2014;25(12):1655-63.

Al-Zahrani AA, Gajewski J. Urodynamic findings in women with refractory overactive bladder symptoms. Int J Urol. 2016;23:75-9.

Zhu J, Hu X, Dong X, Li L. Associations between risk factors and overactive bladder: a meta-analysis. Female Pelvic Med Reconstr Surg. 2019;25:238-46.

Hagovska M, Švihra J, Buková A, Horbacz A, Dračková D, Švihrová V. Comparison of body composition and overactive bladder symptoms in overweight female university students. Eur J Obstet Gynecol Reprod Biol. 2019;237:18-22.

Hsiao SM, Wu PC, Chang TC, Chen CH, Lin HH. Urodynamic and bladder diary factors predict overactive bladder-wet in women: a comparison with overactive bladder-dry. Int Neurourol J. 2019 ;23:69-74.

Jiménez-Cidre MA, López-Fando L, Mora AM. Clinical and urodynamic impact of detrusor overactivity in women with overactive bladder. Actas Urol Esp. 2019;43:221-7.

KoppKallner H, Elmér C, Altman D. Urodynamics as a prognosticator of mirabegron treatment outcomes. Gynecol Obstet Invest. 2019;21:1-5.

Yoo TK, Lee KS, Sumarsono B, Kim ST, Kim HJ, Lee HC, et al. The prevalence of lower urinary tract symptoms in population aged 40 years or over, in South Korea. Investig Clin Urol. 2018 ;59:166-76.

Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence impact questionnaire. 6th edn. International Incontinence Society; 2017.

Monticone M, Frigau L, Mola F, Rocca B, Giordano A, Foti C, et al. Italian versions of the Urogenital Distress Inventory-6 and Incontinence Impact Questionnaire-7: translation and validation in women with urinary incontinence. Disabil Rehabil. 2020; 5:1-7.

Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11:117-25.

Wallace KM, Drake MJ. Overactive bladder. F1000Res. 2015;4.

Homma Y, Fujimura T. Psychometric validation of the English version of the overactive bladder symptom score. Urology. 2014;84:46-50.

Liu M, Wang J, Yang Y, An R, Wen J, Guan Z, et al. Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms. Chin Med J. 2014;127:261-5.

Gotoh M, Kobayashi T, Sogabe K. Impact of symptom improvement on patients’ bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q). Int J Urol. 2014;21:505-11.

Kulaksizoğlu H, Akand M, Çakmakçi E, Gül M, Seçkin B. Effectiveness of pelvic floor muscle training on symptoms and uroflowmetry parameters in female patients with overactive bladder. Turk J Med Sci. 2015;45:449-53.

Fitz F, Sartori M, Girão MJ, Castro R. Pelvic floor muscle training for overactive bladder symptoms - A prospective study. Rev Assoc Med Bras. 2017;63:1032-8.

Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016;8:113-22.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755-65.

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401-7.

Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;25(361):k1315.

Salahudeen MS, Chyou TY, Nishtala PS. Serum anticholinergic activity and cognitive and functional adverse outcomes in older people: a systematic review and meta-analysis of the literature. PLoS One. 2016;11:e0151084.

Shin DG, Kim HW, Yoon SJ, Song SH, Kim YH, Lee YG, et al. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Neurourol Urodyn. 2019;38:295-304.

Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol. 2018;10:411-9.

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70:136-45.

Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3:629-38.

MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacinmonotherapy: responder analyses and patient-reported outcomes from the BESIDE study. J Urol. 2016;196:809-18.

Kuo HC. Individualizing medical treatment of overactive bladder. Ci Ji Yi Xue Za Zhi. 2018;30:195-9.

Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35:827-38.